OSR Holdings, Inc.·Healthcare

BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"), centered on the retirement of approximately $2.02 million of warrant overhang. Elimination of $2.02 Million Warrant Overhang As part of the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them into a newly issued convertible promissory note.

BELLEVUE, WA / ACCESS Newswire / March 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an updated overview of the Company's recent strategic milestones - including its VXM01 oncology asset and Woori IO's noninvasive glucose monitoring platform - and its outlook for continued growth.

NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights recent developments related to the Company's non-invasive glucose monitoring technology (Woori IO), including increasing global interest in potential licensing and distribution opportunities.

BELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders.

BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China.

BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The extension provides the Company until August 31, 2026, to satisfy the rule by achieving a closing bid price of at least $1.00 per share for ten consecutive business days.
OSR Holdings, Inc. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.
Healthcare
Biotechnology
19
2023-03-21
0.59